Intuitive Surgical Inc

In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.

According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.

Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.

Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market.

Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.

After the release of its 2Q16 earnings results on July 28, 2016, Zimmer Biomet Holdings (ZBH) was trading at a forward price-to-earnings multiple in the range of 15.5x–16.2x.

Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.

Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.

Intuitive Surgical is a pioneer of minimally invasive robotic surgery. It develops and manufactures da Vinci surgical systems and related instruments.

Intuitive Surgical (ISRG) defines its business model as a “razor/razor blade” model. What does this mean?

Intuitive Surgical follows a diversified sales strategy and doesn’t generate more than 10% of its revenue through any one customer.

Intuitive Surgical is continuously enhancing its product offerings, enabling more efficient procedures through internal research and development (or R&D).

Intuitive Surgical aims to include a larger patient population under its MIS treatments and to provide better surgery outcomes and lower recovery times.

Coverage, coding, and payment are essential elements to obtaining adequate reimbursement for a new medical device.